Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031

Bone Marrow Transplantation

Volumn 45, Issue 11, 2010, Pages 1653-1657

  Cuvelier, G D E ^a   Kariminia, A ^b   Fujii, H ^c   Aslanian, S ^b   Wall, D ^a   Goldman, F ^d   Grupp, S A ^e   Dunn, S E ^b   Krailo, M ^f   Shapiro, L H ^g   Gilman, A ^h   Schultz, K R ^b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

^d UNIVERSITY OF IOWA   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^h CAROLINAS MEDICAL CENTER   (United States)

Author keywords

aminopeptidase N; anti CD13 Abs; biomarkers; CD13; cGVHD

Indexed keywords

BIOLOGICAL MARKER; ENZYME ANTIBODY; HYDROXYCHLOROQUINE; MICROSOMAL AMINOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE ANTIBODY; PLACEBO; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; BLOOD SAMPLING; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENZYME ACTIVITY; HUMAN; IMMUNOGENICITY; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ANTIBODIES; ANTIGENS, CD13; BIOLOGICAL MARKERS; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; CHRONIC DISEASE; DOUBLE-BLIND METHOD; FEMALE; GRAFT VS HOST DISEASE; HUMANS; HYDROXYCHLOROQUINE; MALE;

EID: 78149465485     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.15     Document Type: Article

References (18)

1. Remberger M, Beelen DW, Fauser A, Basara N, Basu O, Ringden O. Increased risk of extensive chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation using unrelated donors. Blood 2005; 105: 548-551. (Pubitemid 40070735)
2. Kollman C, Howe CW, Anasetti C, Antin JH, Davies SM, Filipovich AH et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age. Blood 2001; 98: 2043-2051.
3. Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with metho-trexate and cyclosporine for graft-versushost disease prophy-laxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303-2314. (Pubitemid 28452971)
4. Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062-2068. (Pubitemid 28452971)
5. Fraser CJ, Bhatia S, Ness K, Carter A, Francisco L, Arora M et al. Impact of chronic graft-versus-host disease on the health status ofhematopoietic cell transplantation survivors: a report from the Bone Marrow Transplant Survivor Study. Blood 2006; 108: 2867-2873.
6. Przepiorka D, Anderlini P, Saliba R, Cleary K, Mehra R, Khouri I et al. Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 2001; 98: 1695-1700.
7. Fujii H, Cuvelier G, She K, Aslanian S, Shimizu H, Kariminia A et al. Biomarkers in newly diagnosed pediatric extensive chronic graft-versus-host disease: A report from the Children's Oncology Group. Blood 2008; 111: 3276-3285.
8. She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z et al. Altered toll-like receptor 9 responses in circulating B cells at the onset ofextensive chronic graft-versus-host disease. Biol Blood Marrow Transplant 2007; 13: 386-397. (Pubitemid 46421893)
9. Luan Y, Xu W. The structure and main functions of aminopeptidase N. Curr Med Chem 2007; 14: 639-647. (Pubitemid 46477717)
10. Dixon J, Kaklamanis L, Turley H, Hickson ID, Leek RD, Harris AL et al. Expression of aminopeptidase-n (CD13) in normal tissues and malignant neoplasms of epithelial and lymphoid origin. J Clin Pathol 1994; 47: 43-47. (Pubitemid 24057748)
11. Soderberg C, Sumitran-Karuppan S, Ljungman P, Moller E. CD13-specific autoimmunity in cytomegalovirus-infected immunocompromised patients. Transplantation 1996; 61: 594-600. (Pubitemid 26073605)
12. Soderberg C, Larsson S, Rozell B, Sumitran-Karuppan S, Ljungman P, Moller E. Cytomegalovirus-induced CD13 specific autoimmunity\a possible cause of chronic graft-versus-host disease. Transplantation 1996; 61: 600-609. (Pubitemid 26073606)
13. Miklos DB, Kim HT, Miller KH, Guo L, Zorn E, Lee SJ et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood 2005; 105: 2973-2978. (Pubitemid 40446295)
14. Svegliati S, Olivieri A, Campelli N, Luchetti M, Poloni A, Trappolini S et al. Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood 2007; 110: 237-241. (Pubitemid 47026840)
15. Soderberg C, Giugni TD, Zaia JA, Larsson S, Wahlberg JM, Moller E. CD13 (human aminopeptidase N) mediates human cytomegalovirus infection. J Virol 1993; 67: 6576-6585. (Pubitemid 23309124)
16. Giugni TD, Soderberg C, Ham DJ, Bautista RM, Hedlund KO, Moller E et al. Neutralization of human cytomegalovirus by humanCD13-specificantibodies. J Infect Dis 1996; 173: 1062-1071.
17. Hansen AS, Noren O, Sjostrom H, Werdelin O. A mouse aminopeptidase N is a marker for antigen presenting cells and appears to be co-expressed with major histocompa-tibility complex class II molecules. Eur J Immunol 1993; 23: 2358-2364. (Pubitemid 23265906)
18. Falk K, Rotzschke O, Stavanovic S, Jung G, Rammensee HG. Pool sequencing of natural HLA-DR, DQ and DP ligands reveal detailed peptide motifs, constraints of processing, and general rules. Immunogenetics 1994; 39: 230-242. (Pubitemid 24064416)